Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Mehra

Showing results (151-160 of 347) with videos related to

Pageof 35
Sort By:
World Journal of Urology|October 18, 2023
Impact of sequencing of androgen receptor-signaling inhibition and radiotherapy in prostate cancer: importance of homologous recombination disruptionSteven G Allen, Chao Zhang, Shawn Malone, et al.
International Journal of Surgical Pathology|May 6, 2026
Retroperitoneal Schwannoma with a Novel <i>PRCC::TFE3</i> Fusion: Expanding the Spectrum of Schwannomas with a <i>TFE3</i> Gene RearrangementKyle D Perry, Rohit Mehra, Ann Leathersich, et al.
Medical Oncology (Northwood, London, England)|February 23, 2024
Evaluation of TRIM63 RNA in situ hybridization (RNA-ISH) as a potential biomarker for alveolar soft-part sarcoma (ASPS)Alexander S Taylor, Rahul Mannan, Liron Pantanowitz, et al.
International Journal of Radiation Oncology, Biology, Physics|March 5, 2017
Pan-Cancer Analysis of Genomic Sequencing Among the ElderlyDaniel R Wahl, Paul L Nguyen, Maria Santiago, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 6, 2007
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancerRohit Mehra, Scott A Tomlins, Ronglai Shen, et al.
Cancer|July 4, 2013
Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomyWilliam Jackson, Daniel A Hamstra, Skyler Johnson, et al.
JCO Precision Oncology|June 6, 2025
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell CarcinomaSteven M Monda, Srinivas Nallandhighal, Ulka Vaishampayan, et al.
Urologic Oncology|December 4, 2019
Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counsellingKevin Ginsburg, Adam I Cole, Michael E Silverman, et al.
Neoplasia (New York, N.Y.)|December 16, 2014
A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancerRohit Mehra, Yang Shi, Aaron M Udager, et al.
The American Journal of Surgical Pathology|March 14, 2017
Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer SyndromesCody S Carter, Stephanie L Skala, Arul M Chinnaiyan, et al.
Pageof 35

Showing results (151-160 of 347) with videos related to

Sort By:
Pageof 35
World Journal of Urology|October 18, 2023
Impact of sequencing of androgen receptor-signaling inhibition and radiotherapy in prostate cancer: importance of homologous recombination disruptionSteven G Allen, Chao Zhang, Shawn Malone, et al.
International Journal of Surgical Pathology|May 6, 2026
Retroperitoneal Schwannoma with a Novel <i>PRCC::TFE3</i> Fusion: Expanding the Spectrum of Schwannomas with a <i>TFE3</i> Gene RearrangementKyle D Perry, Rohit Mehra, Ann Leathersich, et al.
Medical Oncology (Northwood, London, England)|February 23, 2024
Evaluation of TRIM63 RNA in situ hybridization (RNA-ISH) as a potential biomarker for alveolar soft-part sarcoma (ASPS)Alexander S Taylor, Rahul Mannan, Liron Pantanowitz, et al.
International Journal of Radiation Oncology, Biology, Physics|March 5, 2017
Pan-Cancer Analysis of Genomic Sequencing Among the ElderlyDaniel R Wahl, Paul L Nguyen, Maria Santiago, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 6, 2007
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancerRohit Mehra, Scott A Tomlins, Ronglai Shen, et al.
Cancer|July 4, 2013
Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomyWilliam Jackson, Daniel A Hamstra, Skyler Johnson, et al.
JCO Precision Oncology|June 6, 2025
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell CarcinomaSteven M Monda, Srinivas Nallandhighal, Ulka Vaishampayan, et al.
Urologic Oncology|December 4, 2019
Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counsellingKevin Ginsburg, Adam I Cole, Michael E Silverman, et al.
Neoplasia (New York, N.Y.)|December 16, 2014
A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancerRohit Mehra, Yang Shi, Aaron M Udager, et al.
The American Journal of Surgical Pathology|March 14, 2017
Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer SyndromesCody S Carter, Stephanie L Skala, Arul M Chinnaiyan, et al.
Pageof 35